Site 'Tertiary' Navigation:

Page 'Breadcrumb' Navigation:

Press Releases

 
Press Releases
  Date Title and Summary View
Apr 5, 2013
(Salt Lake City, April 5, 2013) - Lipocine Inc. (www.lipocine.com, a biopharmaceutical company focused on developing innovative oral hormone therapies for men's and women's health, today announced favorable Phase I results for LPCN 1111. LPCN 1111, a novel prodrug of testosterone, uses the Company's proprietary Lipâ€&...
Dec 5, 2012
(Salt Lake City, December 5, 2012) - Lipocine Inc. (www.lipocine.com) announced today that the Company recently met with FDA and received guidance and go ahead for the Company's pivotal Phase III study for its oral testosterone replacement therapy (LPCN 1021). Lipocine presented the results of its Phase II trials to FDA that indic...
Jul 6, 2011
Salt Lake City, Utah, July 6, 2011 Lipocine announces that Dr. William Higuchi, Lipocine co-founder and Chairman of the Board, was awarded the 'Order of The Rising Sun' by the Japanese Government for "contribution to the development of Japanese pharmaceutics and pharmaceutical chemistry, as well as to the improvement of social status of Japane...
Jan 28, 2011
Lipocine Inc. Salt Lake City, Utah, January 28, 2011 (www.lipocine.com) announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T)...
Nov 2, 2010
Lipocine Inc. announced today that it has been awarded four cash grants totaling approximately $978,000 under the U.S. Government’s Qualifying Therapeutic Discovery Project (“QTDP”) program. The QTDP program was part of the Patient Protection and Affordable Care Act signed into la...
Page: FirstPrevious ...
10
= add release to Briefcase